ClinicalTrials.gg
Not yet recruitingNCT07859540Updated Oct 28, 2026

Negotiation Training for Family Caregivers of People With Alzheimer's Disease

An interventional study of NegotiAge and PlanYourLifespan in Alzheimer's Disease (AD), Dementia and Cognitive Impairment, sponsored by Northwestern University. Not yet recruiting at 1 site in United States. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Northwestern University · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 28, 2026Start date movedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Alzheimer Disease by Northwestern University — 5 open to participants now, 6 under way, none of them phase 3. Alzheimer Disease · Northwestern University.

Planned enrollment
5th of 15
200 · median 105
Started
2026
with 2 others
No phase
14 of 16
5 open now
Registered
16th of 16
by date

Among the 16 studies in Alzheimer Disease by Northwestern University, this one is the 5th largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2026, is one of 14 with no phase, and was the 16th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

5 of the 16 studies in Alzheimer Disease by Northwestern University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 21 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Alzheimer Disease by Northwestern University, or all of them as a file.
02

Study summary

Family caregivers of people living with Alzheimer's disease and related dementias often experience conflicts and communication challenges when coordinating care, making decisions, and interacting with family members and healthcare providers. These challenges can contribute to caregiver burden, stress, anxiety, and reduced well-being.

The purpose of this study is to evaluate the effectiveness of NegotiAge, an online negotiation and communication training program designed for family caregivers. NegotiAge provides education and interactive practice exercises to help caregivers develop negotiation, problem-solving, conflict-resolution, and communication skills that can be applied to real-world caregiving situations.

Approximately 200 family caregivers will be randomly assigned to either the NegotiAge intervention or an attention-control educational website. Participants will complete online surveys before the intervention, immediately after the intervention, and at 1-month and 3-month follow-up time-points. The study will examine whether NegotiAge reduces caregiver burden and improves communication, conflict-management behaviors, self-efficacy, stress, anxiety, fatigue, and well-being. Findings from this research may help improve support programs for family caregivers of people living with Alzheimer's disease and related dementias.

Read the detailed description

Family caregivers of persons living with Alzheimer's disease and related dementias (ADRD) frequently encounter communication challenges and interpersonal conflicts while coordinating care, making healthcare decisions, advocating for care recipients, and interacting with family members and healthcare professionals. These challenges contribute to caregiver burden, stress, anxiety, and reduced quality of life. Effective communication and conflict-management skills may improve caregivers' ability to navigate complex caregiving situations and support better caregiver outcomes.

NegotiAge is a web-based negotiation and conflict-resolution training intervention developed to improve communication, problem-solving, and conflict-management skills among family caregivers of persons living with ADRD. The intervention includes online educational content and interactive scenario-based exercises that allow participants to practice negotiation and communication strategies in simulated caregiving situations. Scenarios address common caregiving conflicts involving persons living with dementia, family members, healthcare providers, and healthcare systems. Some training activities incorporate automated conversational technology to provide standardized practice opportunities.

This study is a Stage 2 randomized controlled efficacy trial designed to evaluate the effectiveness of NegotiAge. Approximately 200 family caregivers will be randomized in a 1:1 ratio to either the NegotiAge intervention or an attention-control condition consisting of access to an educational website. Participants will complete assessments at baseline, immediately following intervention completion, and at 1-month and 3-month follow-up.

The primary objective is to determine the efficacy of NegotiAge for reducing caregiver burden. Secondary objectives are to evaluate intervention effects on caregiver conflict-management behaviors, stress, anxiety, fatigue, self-efficacy, social well-being, and related psychosocial outcomes. Findings from this study will provide evidence regarding the efficacy of NegotiAge and inform future effectiveness and implementation research aimed at supporting family caregivers of persons living with Alzheimer's disease and related dementias.

This is a fully remote study. Eligible participants may enroll from anywhere within the United States.

03

Conditions studied

  • Alzheimer's Disease (AD)
  • Dementia
  • Cognitive Impairment

Keywords

  • Alzheimer's Disease
  • Dementia
  • Family caregiver
  • Caregiver burden
  • Negotiation training
  • Caregiver communication
  • Behavioral intervention
  • Online intervention
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 21 years or older
  • Self-identify as a family caregiver or unpaid care partner of a person with Alzheimer's disease, a related dementia, cognitive impairment, or memory loss.
  • Provide at least 2 hours per week of assistance, support, advocacy, healthcare coordination, or decision-making for the care recipient.
  • Able to read, understand, and communicate in English.
  • Able and willing to provide .
  • Have regular access to an internet-connected computer, tablet, or smartphone and be comfortable using web-based programs and surveys.
  • Willing to be randomized to either the NegotiAge intervention group or the attention-control group and complete all study assessments.

Exclusion criteria

Exclusion Criteria:

  • Prior participation in PlanYourLifespan studies (STU00209195 or STU00225351).
  • Prior participation in any NegotiAge study (STU00212921).
  • Younger than 21 years of age.
  • Not currently serving as a family caregiver or unpaid care partner for a person with Alzheimer's disease, a related dementia, cognitive impairment, or memory loss.
  • Unable to provide .
  • Unable to read, understand, or communicate in English sufficiently to complete study activities.
  • Significant cognitive impairment or another condition that would prevent meaningful participation in study activities.
  • Lack of access to the technology required for participation in the online intervention and study assessments.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    NegotiAge Intervention

    Participants assigned to this arm will receive access to NegotiAge, a self-paced, web-based negotiation and conflict-resolution training program for family caregivers of persons living with Alzheimer's disease and related dementias. The intervention includes educational modules and interactive scenario-based practice exercises designed to improve communication, negotiation, problem-solving, and conflict-management skills. Participants complete the intervention online using a computer, tablet, or smartphone.

    Behavioral: NegotiAge

  • Active comparator
    PlanYourLifespan Attention-Control

    Participants assigned to this arm will receive access to PlanYourLifespan (PYL), a web-based educational resource that provides information and planning tools related to future healthcare needs, caregiving, hospitalizations, memory loss, communication with family members, and financial planning. Participants may review website content during the study period.

    Behavioral: PlanYourLifespan

Interventions

  • BehavioralNegotiAge

    NegotiAge is a self-paced, web-based negotiation and conflict-resolution training program designed for family caregivers of persons living with Alzheimer's disease and related dementias. The intervention consists of educational modules and interactive scenario-based practice exercises that teach communication, negotiation, problem-solving, and conflict-management skills. Training content addresses common caregiving situations, including communication with persons living with dementia, disagreements among family members, healthcare decision-making, and interactions with healthcare providers and health systems. Participants access the intervention through a secure online platform and complete the training independently using a computer, tablet, or smartphone. Some practice exercises utilize automated conversational technology to provide standardized opportunities to practice negotiation and communication skills in simulated caregiving scenarios.

  • BehavioralPlanYourLifespan

    PlanYourLifespan (PYL) is a web-based educational planning resource that provides information and tools related to future healthcare needs, caregiving, memory loss, family communication, hospitalizations, and financial planning.

06

What researchers measure

Primary outcomes

  1. Change in Zarit Caregiver Burden Score

    The Zarit Burden Interview, a popular caregiver self-report measure used by many aging agencies, originated as a 29-item questionnaire (Zarit, Reever \& Bach-Peterson, 1980). The revised version contains 22 items. Each item on the interview is a statement which the caregiver is asked to endorse using a 5-point scale. Response options range from 0 (Never) to 4 (Nearly Always). The total score range is 0 to 88. Increasing scores indicate increasing burden. Scores were measured at baseline and at 1 month post-intervention and a change score was computed for each participant. These change scores are averaged to produce the by-condition mean change in burden score. Positive results indicate an increase in burden, and negative results indicate a decrease in burden.

    Time frame: 1 month post-intervention

Secondary outcomes

  1. Change in DUTCH Conflict Handling Scores

    The Dutch Test for Conflict Handling measures aspects of conflict resolution pertaining to the negotiator. The DUTCH measures conflict handling in five domains: avoiding, forcing, yielding, problem solving, and compromising. Each domain is measured independently using panels of four 1-5 likert scale questions each. Domain scores thus range from 5-20, converted to 0-100 with the following formula: 6.25\*(domain score-1). Intra-participant change is measured for each subdomain between baseline and 1 month and generalized to produce mean change per domain. Higher scores per domain indicate more intense conflict handling behavior in the given domain- lower scores indicate less intensity.

    Time frame: 1 month post-intervention

  2. Change in PROMIS Anxiety T-Score

    The PROMIS Adult Emotional Distress-Anxiety scale measures self-reported fear (fearfulness, panic), anxious misery (worry, dread), and hyper-arousal (tension, nervousness, restlessness) in respondents during the past 7 days. Each item on the measure is rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always). We deployed the four item short form, with scores ranging from 4-20, with higher scores indicating greater severity of anxiety. The T-score rescales the raw score into a standardized T-score with a mean of 50 and a standard deviation (SD) of 10. Therefore, a person with a T-score of 40 is one SD below the mean. We calculate change in T-Score from baseline to one month per participant and take the mean of those observations to produce mean change in T-score by condition.

    Time frame: 1 month post-intervention

  3. Change in NIH Toolbox Adult Perceived Stress T-Score

    The NIH Toolbox Adult Percieved Stress scale measures self-reported stress experienced by the subject in the past month. Each item on the measure is rated on a 5-point scale (1=never; 2=almost never; 3=sometimes; 4=fairly often; and 5=very often). We deployed the ten item fixed form for adults (18+). Raw scores ranging from 10-50, with higher scores indicating greater perception of stress. The T-score rescales the raw score into a standardized T-score with a mean of 50 and a standard deviation (SD) of 10. Therefore, a person with a T-score of 40 is one SD below the mean. We calculate change in T-Score from baseline to one month per participant and take the mean of those observations to produce mean change in T-score by condition.

    Time frame: 1 month post-intervention

  4. Change in PROMIS Fatigue T-Score

    The PROMIS Fatigue instruments evaluate a range of self-reported symptoms, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. We deployed PROMIS Fatigue Form 7a, a seven item likert scale panel ranging from 1=never to 5=always. Scores range from 7-35. Higher scores indicate more fatigue. The T-score rescales the raw score into a standardized T-score with a mean of 50 and a standard deviation (SD) of 10. Therefore, a person with a T-score of 40 is one SD below the mean. We calculate change in T-Score from baseline to one month per participant and take the mean of those observations to produce mean change in T-score by condition.

    Time frame: 1 month post-intervention

  5. Change in PROMIS General Self Efficacy T-Score

    the PROMIS General Self-Efficacy - Short Form is a four item panel which measures confidence in one's ability to successfully perform specific tasks or behaviors related to one's health in a variety of situations. The four items are 1-5 Likert scales, 1=never, 5=always. Minimum score is a 4 and maximum is a 20. Raw Scores are converted to T scores with mean 50 and SD 10 per the PROMIS scoring manual. Higher score=greater self efficacy.

    Time frame: 1 month post-intervention

  6. Change in Neuro-QoL Positive Affect and Well-being T-Score

    Caregiver well-being as measured by the Positive Affect and Well-being scale for the Neurology Quality of Life (Neuro-QOL). The measure is a 9-item panel rating how caregivers experience feelings of positive affect and well-being. Responses are Likert scales, scored 1-5, Never (1), Rarely (2), Sometimes (3), Often (4), Always (5). Responses are summed for a final score and converted to a t-score per Neuro-QoL manual scoring conventions. Population mean T-Score is 50 and SD is 10. Higher scores indicate higher levels of Positive Affect and Well-Being. Positive change represents an increase in positive affect/well-being, and negative change represents a decrease.

    Time frame: 1 month post-intervention

Other outcomes

  1. Change in Negotiation Knowledge scores

    We deployed a panel of 15 questions measuring participant knowledge of negotiation techniques. The panel measures knowledge in three subdomains (identification of interests, rights, and power statements) and can also be measured in aggregate to assess knowledge across the three subdomains. Participants receive 1 point for each correct answer. All Scores, including subdomain scores, are converted to a 0/100 measure. Intraparticipant change is assessed between baseline and 1 month post-intervention. Dependent Sample T-Tests were performed on the change scores from baseline-1 month.

    Time frame: 1 month post-intervention

  2. Change in Positive and Negative Affect Schedule Scores

    The Positive and Negative Affect Schedule (PANAS) is a self-report questionnaire that consists of two 10-item scales to measure both positive and negative affect. Each item is rated on a 5-point verbal frequency scale of 1 (not at all) to 5 (very much). Scores are evaluated out of 50. The ten item scales thus have score ranges from 10-50. Higher scores in a single domain indicate greater perception of that type of affect. So, higher positive affect scores=greater positive affect, and higher negative affect scores=higher negative affect. Positive change on either scale indicates an increase in that domain, and negative change on either scale indicates a decrease in that domain.

    Time frame: 1 month post-intervention

07

Study locations

1 site
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
    • Lee A Lindquist, MD, MPH, MBA · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data collected during the study, including demographic characteristics, caregiving experiences, caregiver burden, conflict-management behaviors, stress, anxiety, fatigue, self-efficacy, social well-being, intervention engagement measures, and other study outcomes assessed at baseline, post-intervention, 1-month follow-up, and 3-month follow-up. Direct identifiers will not be included in shared datasets.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Apr 2028, 16 months later.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 16 months is below that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

Start moved once since we started tracking on Sep 25, 2026: Nov 2026 → Dec 2026, on Oct 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 5, 2026
StartEst.
Dec 2026was Nov 2026
Primary completionEst.
Apr 2028
CompletionEst.
Aug 31, 2028
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Nov 2026→Dec 2026
Oct 28, 2026
Registered
First appeared on the registry
Oct 5, 2026
Show all 2 updates
  1. Oct 28, 2026
    Start date Nov 2026→Dec 2026
    + 1 other change: verification date
  2. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07859540
Responsible party
Lee Lindquist (Professor, Northwestern University) — Principal investigator
First posted
Oct 5, 2026
Start date
Dec 2026 (estimated)
Primary completion
Apr 2028 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Oct 28, 2026

Study contacts

Alaine Murawski
Contact
negotiage@northwestern.edu
(312) 503-7981
Vanessa Ramirez-Zohfeld
Contact
vanessa-ramirez-0@northwestern.edu
(312) 503-3916

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion